For five years, the mystery went cold. Then, in September 2023, a programmer scraping old FTP servers found a text file named README_KBI110.txt . It contained a single line of English text, which is unusual given the Japanese origins of the myth:

KBI-110 is a proprietary, patented compound developed by a leading biotechnology company. The exact composition and structure of KBI-110 are not publicly disclosed, but it is known to be a specially designed molecule that interacts with specific biological pathways. This unique interaction enables KBI-110 to modulate various physiological processes, leading to a range of beneficial effects.

The designation represents the practical application of BCS Class I science. When a pharmaceutical company develops a generic version of a Class I drug, they can file for a Biowaiver.

The release of marked a shift for the Kani Bijin label. Following the audience reception to this darker, more arthouse entry, the label announced a shift in strategy. Subsequent releases (KBI-113 onwards) have shown a blend of the "slow cinema" techniques perfected in KBI-110 with more accessible plots.